Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | ACHE | P22303 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865892 | 0.86 | PDE10A (0.43) | PDE10AACHENPC1MEN1KMT2A | |
| SCHEMBL9972450 | 0.82 | ALOX15 (0.47) | PDE10AKMT2ASMN1; SMN2MAPT | |
| SCHEMBL31332579 | 0.76 | HDAC6 (0.54) | PDE10ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL30696154 | 0.76 | SMN1; SMN2 (0.48) | ACHENPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28314002 | 0.74 | NPC1 (0.53) | ACHENPC1MEN1KMT2ARAB9A | |
| SCHEMBL9058089 | 0.73 | NPC1 (0.49) | ACHENPC1MEN1KMT2ARAB9A | |
| SCHEMBL31120328 | 0.73 | HDAC6 (0.56) | PDE10ANPC1MEN1KMT2ARAB9A | |
| SCHEMBL1442308 | 0.73 | HTR1A (0.47) | — | |
| SCHEMBL31120345 | 0.71 | PDE10A (0.44) | PDE10AACHENPC1MEN1KMT2A | |
| SCHEMBL31120289 | 0.71 | PDE10A (0.44) | PDE10AACHENPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546402-B2 | Chromone derivatives, a process for their preparation and their therapeutic applications | SOKOLOFF PIERRE (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546402-B2 | Chromone derivatives, a process for their preparation and their therapeutic applications | SOKOLOFF PIERRE (FR) | 2013-10-01 | — | — | US | disclosed |
| EP-2470520-B1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PF MEDICAMENT (FR) | 2013-07-17 | — | — | EP | disclosed |
| EP-2470520-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | Pierre Fabre Medicament (FR) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-21 | — | — | US | disclosed |
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027289-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | PIERRE FABRE MEDICAMENT (FR) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157463-A1 | CHROMONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | CHRNA3, CHRM3, VDR | PDE10A 594/4885ACHE 60/4885NPC1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.